|Bid||285.55 x 0|
|Ask||285.70 x 0|
|Day's Range||284.55 - 289.30|
|52 Week Range||249.60 - 354.80|
|PE Ratio (TTM)||18.53|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||330.43|
Bagsværd, Denmark, 16 April 2018 - On 5 February 2018, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council ...
Bagsværd, Denmark, 9 April 2018 - On 5 February 2018, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council ...
Novo Nordisk (NVO) secures a global licence for United States' biotech company EpiDestiny's sickle cell disease program EPI01.
Danish drugmaker Novo Nordisk has secured the global licence for U.S. biotech company EpiDestiny's sickle cell disease (SCD) programme in a bid to offset declining sales in its biopharmaceutical business. Novo, best known for its diabetes drugs, is on the hunt for promising assets to boost its struggling blood products business after it lost out to French rival Sanofi in the chase for Belgian biotech company Ablynx in January. "This is a great opportunity for Novo Nordisk to enter into a new therapeutic area closely related to our existing biopharmaceutical business," said chief scientific officer Mads Krogsgaard Thomsen.
Bagsværd, Denmark, 3 April 2018 - In continuation of the company`s announcements dated 1 November 2017 and 5 February 2018 concerning planned share repurchase programmes, and pursuant to Section 204.25 ...
Bagsværd, Denmark, 26 March 2018 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an update to the US prescribing information for Tresiba ® (insulin degludec) ...
A dozen drugs launching in 2018 from heavy-hitters like Roche, Gilead and J&J are expected to hit blockbuster status over the next five years, an analytics firm predicted Thursday.
Bagsværd, Denmark, 23 March 2018 - Novo Nordisk today announced that the Japanese Ministry of Health, Labour and Welfare has approved Ozempic ® (semaglutide), a new once-weekly analogue of human glucagon-like ...
Leading diabetes drugmaker Novo Nordisk (NOVOb.CO) has named former oil boss Helge Lund as its new chairman as the company contends with increasing price pressure and seeks acquisitions to broaden its blood products line-up. The man dubbed by some as Norway's Mr Oil because of his extensive career in the oil and gas industry may be more of an expert in hydrocarbons than insulin, but his merger and acquisitions experience is a big draw for the Danish pharmaceuticals company.
Bagsværd, Denmark, 12 March 2018 - On 5 February 2018, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council ...
Novo Nordisk CEO Lars Fruergaard Jorgensen discusses challenges facing the drug industry, the U.S. healthcare system and Brexit. He speaks on "Bloomberg Markets." (Source: Bloomberg)
A $165 million (£119 million) venture fund focused on tackling "superbugs" resistant to modern antibiotics has been launched to invest in small companies working on novel medicines. Backed by Novo Holdings, which has big stakes in Danish drugmaker Novo Nordisk and enzymes specialist Novozymes, the new Repair Impact Fund will invest $20-40 million a year over three to five years in about 20 projects in Europe and the United States. Novo said on Wednesday its new fund would invest in start-ups, early-stage companies and corporate spin-outs, either as the sole investor or in a syndicate.
The world's largest diabetes drugmaker Novo Nordisk on Thursday presented the first successful data from a final-stage study for a pill it hopes will transform the diabetes market. The oral form of the drug, known generically as semaglutide, is crucial for ensuring the group's long-term growth, as price pressure has been mounting in a crowded market targeting the world's 450 million diabetics. Novo Nordisk said the first of 10 phase III trials were successful in its primary objective by demonstrating "significant and superior" improvements in long-term blood sugar compared to a placebo.
Bagsværd, Denmark, 22 February 2018 - Novo Nordisk today announced the headline results from PIONEER 1, the first phase 3a trial with oral semaglutide for treatment of adults with type 2 diabetes. Oral ...
Insulin maker Novo Nordisk said its Ozempic diabetes drug had been included on a list of medicines approved for patients covered by U.S. private health schemes, setting the stage for a battle with Eli Lilly's Trulicity. Novo Nordisk, the world's biggest insulin maker, launched Ozempic, known generically as semaglutide, in the United States this year after it was approved by the U.S. Food and Drug Administration in December. Ozempic is a once-weekly injection that Novo Nordisk hopes will take market share from Trulicity, which has been cutting into sales of Novo Nordisk's once-daily Victoza.
Bagsværd, Denmark, 19 February 2018 - On 5 February 2018, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council ...
Bagsværd, Denmark, 13 February 2018 - This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company`s board members, executives and their associated persons in accordance ...
Mar.02 -- Novo Nordisk CEO Lars Fruergaard Jorgensen discusses challenges facing the drug industry, the U.S. healthcare system and Brexit. He speaks on "Bloomberg Markets."